SUB-RETINAL FLUID (SRF) AS A PROTECTIVE FACTOR AGAINST MACULAR ATROPHY AND POSITIVE RETINAL BIOMARKER OF VISUAL OUTCOME

Jana Nivichka Kjaeva; Natasha Trpevska Shekerinov; Igor Isjanovski; Andrijana Petrushevska; Gazmend Memedi

Jana Nivichka Kjaeva University Clinic for Eye Diseases, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Natasha Trpevska Shekerinov University Clinic for Eye Diseases, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Igor Isjanovski University Clinic for Eye Diseases, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Andrijana Petrushevska University Clinic for Eye Diseases, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Gazmend Memedi University Clinic for Eye Diseases, Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Age related macular degeneration is the leading cause of legal blindness in elderly people. Its prevalence increases significantly after the age of 50. Neovascular, exudative AMD accounts for less than 10% of cases, the wet form (nAMD) is responsible for the largest number of cases where severe central visual impairment occurs compared to the dry form of AMD. Neovascular AMD form is characterized by the growth of abnormal choroidal new blood vessels from pre-existing choriocapillaris vessels. The exudation resulting from the immaturity of the blood vessels resulting in accumulation of fluids in different retinal compartments depending on the MVN (macular neovascular ) extension and localization. Subretinal fluid is an exudation that is localized in the space between the neurosensory retina and the retinal pigment epithelium. VEGF-A plays a key role in the process of angiogenesis and vascular permeability. Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in the treatment of numerous retinal diseases, most notably exudative age-related macular degeneration (eAMD), diabetic retinopathy and retinal vein occlusions, offering significant functional and anatomic benefits in most of the patients. Of all retinal biomarkers subretinal fluid (SRF) is the only imaging biomarker, that is, the only "pathological" morphological parameter that is consistently associated with a positive effect on visual acuity and has protective role against development of macular atrophy.

Kew words: wet AMD, sub-retinal fluid, anti-VEGF treatment, macular atrophy.

References

1.Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open [Internet]. 2016 Dec;6(12):e011504. Available from: https://bmjopen.bmj.com/content/6/12/e011504
2.Singh SR, Lupidi M, Mishra SB, Paez-Escamilla M, Querques G, Chhablani J. Unique optical coherence tomographic features in age-related macular degeneration. Surv Ophthalmol. 2020;65(4):451–457. doi:10.1016/j.survophthal.2020.01.001
3.Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006.
4.Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020.
5.Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004.
6.Chakravarthy U, Bailey CC, Scanlon PH, McKibbin M, Khan RS, Mahmood S. Progression from early/intermediate to advanced forms of age-related macular degeneration in a large UK cohort: rates and risk factors. Ophthalmol Retina. 2020 Jul.
7.Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A. Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules. Int J Mol Sci. 2019 Apr.
8.Lujan BJ, Roorda A, Croskrey JA, Dubis AM, Cooper RF, Bayabo JK. Directional optical coherence tomography provides accurate outer nuclear layer and Henle fiber layer measurements. Retina. 2015 Aug.
9.Mitamura Y, Mitamura-Aizawa S, Katome T, Naito T, Hagiwara A, Kumagai K. Photoreceptor impairment and restoration on optical coherence tomographic image. J Ophthalmol. 2013.
10.Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018.
11.Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860–1870.
12.Sato T, Suzuki M, Ooto S, Spaide RF. Multimodal imaging findings and multimodal vision testing in neovascular age-related macular degeneration. Retina. 2015;35:1292–1302.
13.Gianniou C, Dirani A, Jang L, Mantel I. Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab: functional and structural outcome.
14.Ahlers C, Gotzinger E, Pircher M, Golbaz I, Prager F, Schutze C, Baumann B, Hitzenberger CK, Schmidt-Erfurth U. Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51:2149–2157.